| Symbol | TENX |
|---|---|
| Name | TENAX THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | ONE COPLEY PARKWAY,SUITE 490, MORRISVILLE, North Carolina, 27560, United States |
| Telephone | +1 919 855-2100 |
| Fax | — |
| — | |
| Website | https://www.tenaxthera.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000034956 |
| Description | Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). For more information, visit www.tenaxthera.com. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - TENAX THERAPEUTICS, INC. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001193125-26-352960 <b>Size:</b> 13 KB
Read moreNew Form SCHEDULE 13G/A - TENAX THERAPEUTICS, INC. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001193125-26-352650 <b>Size:</b> 11 KB
Read moreNew Form SCHEDULE 13G/A - TENAX THERAPEUTICS, INC. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001231919-26-000935 <b>Size:</b> 18 KB
Read moreNew Form SCHEDULE 13G/A - TENAX THERAPEUTICS, INC. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000921895-26-002186 <b>Size:</b> 28 KB
Read moreNew Form SCHEDULE 13G/A - TENAX THERAPEUTICS, INC. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001213900-26-090068 <b>Size:</b> 11 KB
Read moreTENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX)
Read moreNew Form SCHEDULE 13G/A - TENAX THERAPEUTICS, INC. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001493215-26-000159 <b>Size:</b> 11 KB
Read moreTENX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Tenax Therapeutics
Read moreTenax Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Tenax Therapeutics (TENX)
Read moreNew Form SCHEDULE 13G/A - TENAX THERAPEUTICS, INC. <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0000919574-26-004973 <b>Size:</b> 13 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT02973620 | Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensate… | — | Heart Decompensation | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT07436689 | Long-Term Open-Label Extension Study of Oral Levosimendan | Phase3 | Pulmonary Hypertension Associated With HFpEF | Enrolling_By_Invitation | 2026-03-13 | 2029-03-01 | ClinicalTrials.gov |
| NCT07288398 | LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 | Phase3 | Pulmonary Hypertension Associated With HFpEF | Recruiting | 2026-03-03 | 2029-06-30 | ClinicalTrials.gov |
| NCT05983250 | LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF | Phase3 | Pulmonary Hypertension | Active_Not_Recruiting | 2024-01-10 | 2028-10-30 | ClinicalTrials.gov |
| NCT03624010 | Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients | Phase2 | Hypertension Pulmonary Secondary Heart Failure | Completed | 2019-04-09 | 2023-04-25 | ClinicalTrials.gov |
| NCT03541603 | Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF | Phase2 | Hypertension Pulmonary Secondary | Completed | 2018-11-14 | 2020-04-07 | ClinicalTrials.gov |
| NCT02025621 | Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing … | Phase3 | Coronary Artery Bypass Grafting | Completed | 2014-07-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT00908063 | Safety and Tolerability of Oxycyte in Patients With Traumatic Brain Injury (TBI) | Phase2 | Traumatic Brain Injury | Terminated | 2009-10-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT00174980 | Study of Oxycyte in Severe Closed Head Injury | Phase2 | Traumatic Brain Injury | Terminated | 2005-09-01 | 2008-04-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE3 | Pulmonary Hypertension | ACTIVE_NOT_RECRUITING | NCT05983250 |
| TNX-103 | Other | Phase PHASE3 | Pulmonary Hypertension | ACTIVE_NOT_RECRUITING | NCT05983250 |
| Placebo | Other | Phase PHASE3 | Pulmonary Hypertension | ACTIVE_NOT_RECRUITING | NCT05983250 |
| TNX-103 | Other | Phase PHASE3 | Pulmonary Hypertension | ACTIVE_NOT_RECRUITING | NCT05983250 |
| TNX-103 | Other | Phase PHASE3 | Pulmonary Hypertension Associated With HFpEF | ENROLLING_BY_INVITATION | NCT07436689 |
| Levosimendan | Other | Preclinical | Heart Decompensation | NO_LONGER_AVAILABLE | NCT02973620 |
| Placebo | Other | Phase PHASE3 | Coronary Artery Bypass Grafting | COMPLETED | NCT02025621 |
| Levosimendan | Other | Phase PHASE3 | Coronary Artery Bypass Grafting | COMPLETED | NCT02025621 |
| Matching Placebo | Other | Phase PHASE2 | Hypertension Pulmonary Secondary | COMPLETED | NCT03541603 |
| Levosimendan | Other | Phase PHASE2 | Hypertension Pulmonary Secondary | COMPLETED | NCT03541603 |
| Placebo | Other | Phase PHASE3 | Pulmonary Hypertension | RECRUITING | NCT05983250 |
| TNX-103 | Other | Phase PHASE3 | Pulmonary Hypertension | RECRUITING | NCT05983250 |
| Placebo | Other | Phase PHASE3 | Pulmonary Hypertension Associated With HFpEF | RECRUITING | NCT07288398 |
| TNX-103 | Other | Phase PHASE3 | Pulmonary Hypertension Associated With HFpEF | RECRUITING | NCT07288398 |
| TNX-103 | Other | Phase PHASE3 | Pulmonary Hypertension Associated With HFpEF | ENROLLING_BY_INVITATION | NCT07436689 |
| Levosimendan | Other | Phase PHASE2 | Hypertension Pulmonary Secondary Heart Failure | COMPLETED | NCT03624010 |
| Levosimendan | Other | Phase PHASE2 | Hypertension Pulmonary Secondary Heart Failure | COMPLETED | NCT03624010 |
| Levosimendan | Other | Phase PHASE2 | Hypertension Pulmonary Secondary Heart Failure | COMPLETED | NCT03624010 |
| Levosimendan | Other | Phase PHASE2 | Hypertension Pulmonary Secondary Heart Failure | COMPLETED | NCT03624010 |
| Levosimendan | Other | Phase PHASE2 | Hypertension Pulmonary Secondary Heart Failure | COMPLETED | NCT03624010 |
| Levosimendan | Other | Phase PHASE2 | Hypertension Pulmonary Secondary Heart Failure | COMPLETED | NCT03624010 |
| Levosimendan | Other | Phase PHASE2 | Hypertension Pulmonary Secondary Heart Failure | COMPLETED | NCT03624010 |
| Levosimendan | Other | Phase PHASE2 | Hypertension Pulmonary Secondary Heart Failure | COMPLETED | NCT03624010 |
| Levosimendan | Other | Phase PHASE2 | Hypertension Pulmonary Secondary Heart Failure | COMPLETED | NCT03624010 |
| TNX-103 | DRUG | Phase PHASE3 | Pulmonary Hypertension Associated With HFpEF | ENROLLING_BY_INVITATION | NCT07436689 |
| Levosimendan 2.5 mg/ml Injectable Solution | DRUG | Phase PHASE2 | Hypertension Pulmonary Secondary Heart Failure | COMPLETED | NCT03624010 |
| Matching Placebo | DRUG | Phase PHASE2 | Hypertension Pulmonary Secondary | COMPLETED | NCT03541603 |
| Placebo | DRUG | Phase PHASE3 | Pulmonary Hypertension Associated With HFpEF | RECRUITING | NCT07288398 |
| Levosimendan | DRUG | Phase PHASE2 | Hypertension Pulmonary Secondary | COMPLETED | NCT03541603 |
| Normal Saline | DRUG | Phase PHASE2 | Traumatic Brain Injury | TERMINATED | NCT00908063 |
| Oxycyte | DRUG | Phase PHASE2 | Traumatic Brain Injury | TERMINATED | NCT00908063 |